Trial site
Hospices Civils de Lyon - Hopital Louis Pradel
Bron, 69500, FranceNot linked to an institution yet
- 15running trials
- 1closed trial
The trials here
What the 16 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 1/21 trial
- Phase 21 trial
- Status
- Recruiting8 trials
- Active, not recruiting4 trials
- Not yet recruiting3 trials
- Completed1 trial
- Lead sponsor
- Eli Lilly and Company4 trials
- Hospices Civils de Lyon2 trials
- Assistance Publique - Hôpitaux de Paris1 trial
- Boston Scientific Corporation1 trial
- Dizal Pharmaceuticals1 trial
- and 7 more
Running trials
Not yet recruiting
An Optimization Study Evaluating Safety and Efficacy of the Y-90 Glioblastoma (GBM) Device in Patients With Recurrent GBM
NCT07867886· Boston Scientific Corporation· Source
Contact: Pauline Bonazza
Not yet recruiting
ACetazolamide in Patients With Heart Failure, to Decrease Weight and relIEVE Symptoms.
NCT07737964· Phase 3· University Hospital, Montpellier· Source
Recruiting
A Non-Investigational Product, Multi-Center Cohort Study to Describe Long-Term Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec
2025-523660-21-00· Phase 3· Pfizer Inc.· Source
Recruiting
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222137· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· Phase 3· Eli Lilly and Company· Source
Contact: Michael Duruisseaux (principal investigator)
Active, not recruiting
Medico-economic Analysis of Clinical Pharmacy Activities
NCT07133152· Hospices Civils de Lyon· Source
Recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· Phase 3· Eli Lilly and Company· Source
Recruiting
Cohort of STEMI Patients 2
NCT05794022· Hospices Civils de Lyon· Source
Contact: Thomas BOCHATON, Dr
Recruiting
Incidence and Morbidity of Cardiac Rhythm Disorders in Patients Assisted by ECMO-VA for Refractory Cardiogenic Shock
NCT05788120· Assistance Publique - Hôpitaux de Paris· Source
Contact: FELLAHI Pr Jean-Luc
Recruiting
Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study
NCT05692999· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Active, not recruiting
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238· Phase 3· Novo Nordisk A/S· Source
Recruiting
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
NCT05568719· Phase 3· Pfizer· Source
Active, not recruiting
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
NCT03974022· Phase 1/2· Dizal Pharmaceuticals· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error